Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Inventiva
  6. Summary
    IVA   FR0013233012

INVENTIVA

(IVA)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Real-time Quote. Real-time Euronext Paris
07/23/2021 07/26/2021 07/27/2021 07/28/2021 07/29/2021 Date
12.06(c) 11.66(c) 11.64(c) 11.5(c) 11.36(c) Last
10 028 14 622 20 156 16 210 33 963 Volume
-1.15% -3.32% -0.17% -1.20% -1.22% Change
More quotes
Estimated financial data (e)
Sales 2021 3,42 M 4,06 M 4,06 M
Net income 2021 -51,4 M -61,1 M -61,1 M
Net cash position 2021 72,0 M 85,5 M 85,5 M
P/E ratio 2021 -8,39x
Yield 2021 -
Sales 2022 1,75 M 2,08 M 2,08 M
Net income 2022 -71,5 M -85,0 M -85,0 M
Net Debt 2022 3,55 M 4,22 M 4,22 M
P/E ratio 2022 -5,35x
Yield 2022 -
Capitalization 439 M 522 M 521 M
EV / Sales 2021 107x
EV / Sales 2022 253x
Nbr of Employees 91
Free-Float 72,7%
More Financials
Company
Inventiva SA is a France-based company engaged in the biotechnology sector. The Company focuses on the development of therapies in the area of oncology, fibrosis and rare diseases. The CompanyÔÇÖs pipeline comprises a number of development programs, such as Clinical Pipeline, Preclinical Pipeline, AbbVie Collaboration and Boehringer-Ingelheim collaboration. Its drug candidates target at the treatment of... 
More about the company
Ratings of Inventiva
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
-
More Ratings
All news about INVENTIVA
07/28INVENTIVA : Reports First-Half of 2021 Financial Information
GL
07/22INVENTIVA : Half-yearly review of the liquidity contract with Kepler Cheuvreux
PU
07/22INVENTIVA : Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuv..
GL
07/20INVENTIVA : Half-Year Review of Inventiva's Liquidity Contract with Kepler Cheuv..
PU
07/02INVENTIVA : Corporate Presentation July 2021
PU
06/15INVENTIVA TO PARTICIPATE AT THE SVB : Liver Disease Day
GL
06/09Inventiva announces three scientific presentations at the EASL International ..
GL
05/25INVENTIVA : to participate at the Jefferies Virtual Healthcare Conference
GL
05/14INVENTIVA : reports first quarter 2021 financial information and updates on the ..
PU
05/13GLOBAL MARKETS LIVE : Walt Disney, Canada Goose, Tod's, Burberry, Sonos...
05/13INVENTIVA : AbbVie to Initiate Phase 2B Study of Autoimmune Disease Drug
MT
05/12Inventiva reports first quarter 2021 financial information and updates on the..
GL
05/12INVENTIVA : reports first quarter 2021 financial information and updates on the ..
GL
05/12Inventiva Reports Financial Results for the First Quarter Ended March 31, 202..
CI
05/12Inventiva Updates on the Collaboration with Abbvie in Auto-Immune Diseases
CI
More news
News in other languages on INVENTIVA
07/28INVENTIVA : présente ses informations financières du 1er semestre 2021
07/22INVENTIVA : Bilan semestriel du contrat de liquidité avec Kepler Cheuvreux
07/22INVENTIVA : Bilan semestriel du contrat de liquidité de la société Inventiva con..
07/20INVENTIVA : Bilan semestriel du contrat de liquidité de la sociéte&#..
07/13LES MARCHÉS EN VACANCES : Emission du 13 juillet 2021
More news
Analyst Recommendations on INVENTIVA
More recommendations
Chart INVENTIVA
Duration : Period :
Inventiva Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends INVENTIVA
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 9
Last Close Price 11,36 €
Average target price 26,59 €
Spread / Average Target 134%
EPS Revisions
Managers and Directors
FrÚdÚric Cren Chairman & Chief Executive Officer
Jean Volatier Chief Financial & Administrative Officer
Pierre Broqua Director, Deputy CEO & Chief Scientific Officer
Michael P. Cooreman Chief Medical Officer
Chris Buyse Independent Director
Sector and Competitors
1st jan.Capi. (M$)
INVENTIVA-3.07%525
GILEAD SCIENCES, INC.20.25%87 868
BIONTECH SE283.45%75 705
WUXI APPTEC CO., LTD.38.94%68 994
REGENERON PHARMACEUTICALS21.38%60 726
VERTEX PHARMACEUTICALS-15.22%52 353